Introduction to InnoThyroGen at the 62nd Oncology Congress

From 11 to 15 November 2025, Belgrade hosted the 62nd Oncology Congress, one of the leading regional events dedicated to the advancement of oncology, diagnostics and personalized therapy.
The congress gathered medical doctors, researchers, pharmacists, laboratory specialists and many other healthcare professionals.
During this important event, Dr. Branka Zukić from IMGGE represented the InnoThyroGen project and participated over two consecutive days, contributing through both a scientific lecture and a moderated panel discussion.

Day 1: InnoThyroGen at the 62nd Oncology Congress Through a Plenary Lecture

On the first day, Dr. Zukić delivered a lecture titled:
“Integrating Genomic Medicine into Serbia’s Healthcare System: From Pilot Projects to Systemic Transformation.”

During her talk, she emphasized ongoing efforts by Serbian researchers to translate scientific findings into molecular diagnostic methodologies.
These methodologies support precision oncology and personalized therapy, enabling more accurate patient stratification and improved treatment outcomes.
Furthermore, she highlighted the importance of making such advanced diagnostics accessible to all patients in Serbia, ensuring equity in healthcare.

In addition, Dr. Zukić discussed several activities carried out within the InnoThyroGen project. She presented ongoing work on personalized ecosystem mapping and stakeholder identification, both essential for supporting genomic medicine and strengthening the project’s long-term impact.

Impact of the Day 1 Lecture

The lecture helped introduce the InnoThyroGen project to a large audience of oncology-focused professionals.
As a result, several important outcomes were achieved:

• Increased awareness of Serbia’s progress in genomic medicine
• Better understanding of the role that precision diagnostics can play in oncology
• Stronger visibility of InnoThyroGen among clinicians and molecular experts
• Improved recognition of ecosystem mapping as a tool for future healthcare transformation

Consequently, the project’s scientific value and long-term objectives became clearer to national and regional stakeholders.

Day 2: InnoThyroGen at the 62nd Oncology Congress Through a Panel Discussion

On the second day, Dr. Zukić moderated the panel “Innovating Together: When Research Meets Clinical Practice.”
The discussion explored how collaboration between clinicians and researchers can create a more responsive and innovative healthcare system.

Panelists highlighted the importance of embedding research and development directly within clinical settings.
As a result, scientific discoveries can move more quickly into practical use, while clinicians receive tools that genuinely improve their everyday work.
Furthermore, the dialogue pointed out that synergy between research and practice is essential for ensuring continuous improvement in patient outcomes.

Impact of the Day 2 Panel

During the discussion, participants stressed the importance of teamwork and cross-sector cooperation.
Additionally, the panel showcased the InnoThyroGen project as an example of how regional healthcare ecosystem mapping and structured pathways for translation can produce meaningful impact.

Key outcomes included:

• Increased interest in building a strong personalized healthcare ecosystem
• Greater recognition of stakeholder collaboration as a foundation for innovation
• Stronger visibility of EU-funded initiatives as tools for accelerating genomic medicine
• Deeper understanding of InnoThyroGen’s relevance in integrating research and clinical practice

Overall, InnoThyroGen at the 62nd Oncology Congress demonstrated how coordinated efforts can strengthen research capacity and support clinical implementation across the region.

Conclusion

The 62nd Oncology Congress in Belgrade provided an excellent platform for presenting scientific progress and fostering dialogue between clinical and research communities.
Through both her lecture and panel moderation, Dr. Zukić successfully highlighted the importance of genomic medicine, collaboration and long-term ecosystem development.
Therefore, InnoThyroGen at the 62nd Oncology Congress continues to contribute to the transformation of oncology and personalized healthcare in Serbia.

Stay Tuned

Stay tuned for more updates from upcoming scientific events.
Additionally, follow InnoThyroGen on LinkedIn, X (Twitter), Facebook and Instagram for new activities, announcements and research insights.